These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35604465)

  • 1. Patients with multiple sclerosis: a burden and cost of illness study.
    Battaglia MA; Bezzini D; Cecchini I; Cordioli C; Fiorentino F; Manacorda T; Nica M; Ponzio M; Ritrovato D; Vassallo C; Patti F
    J Neurol; 2022 Sep; 269(9):5127-5135. PubMed ID: 35604465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic burden of multiple sclerosis in Slovakia - from 2015 to 2020.
    Babela R; Dugas J
    BMC Health Serv Res; 2022 Dec; 22(1):1467. PubMed ID: 36461018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insights into the burden and costs of multiple sclerosis in Europe: Results for Italy.
    Battaglia M; Kobelt G; Ponzio M; Berg J; Capsa D; Dalén J;
    Mult Scler; 2017 Aug; 23(2_suppl):104-116. PubMed ID: 28643600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs.
    Bebo B; Cintina I; LaRocca N; Ritter L; Talente B; Hartung D; Ngorsuraches S; Wallin M; Yang G
    Neurology; 2022 May; 98(18):e1810-e1817. PubMed ID: 35418457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct and indirect economic consequences of multiple sclerosis in Ireland.
    Fogarty E; Walsh C; McGuigan C; Tubridy N; Barry M
    Appl Health Econ Health Policy; 2014 Dec; 12(6):635-45. PubMed ID: 25227118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact on healthcare resource utilization of multiple sclerosis in Spain.
    Sicras-Mainar A; Ruíz-Beato E; Navarro-Artieda R; Maurino J
    BMC Health Serv Res; 2017 Dec; 17(1):854. PubMed ID: 29284493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Burden of illness of multiple sclerosis: Part I: Cost of illness. The Canadian Burden of Illness Study Group.
    Can J Neurol Sci; 1998 Feb; 25(1):23-30. PubMed ID: 9532277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perspectives in multiple sclerosis health care: special focus on the costs of multiple sclerosis.
    Rotstein Z; Hazan R; Barak Y; Achiron A
    Autoimmun Rev; 2006 Oct; 5(8):511-6. PubMed ID: 17027884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The economic impact of multiple sclerosis in Australia in 2010.
    Palmer AJ; Colman S; O'Leary B; Taylor BV; Simmons RD
    Mult Scler; 2013 Oct; 19(12):1640-6. PubMed ID: 23652216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy.
    Amato MP; Battaglia MA; Caputo D; Fattore G; Gerzeli S; Pitaro M; Reggio A; Trojano M;
    J Neurol; 2002 Feb; 249(2):152-63. PubMed ID: 11985380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost analysis of multiple sclerosis in Brazil: a cross-sectional multicenter study.
    da Silva NL; Takemoto MLS; Damasceno A; Fragoso YD; Finkelsztejn A; Becker J; Gonçalves MVM; Tilbery C; de Oliveira EML; Callegaro D; Boulos FC
    BMC Health Serv Res; 2016 Mar; 16():102. PubMed ID: 27009599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost of disorders of the brain in Europe 2010.
    Gustavsson A; Svensson M; Jacobi F; Allgulander C; Alonso J; Beghi E; Dodel R; Ekman M; Faravelli C; Fratiglioni L; Gannon B; Jones DH; Jennum P; Jordanova A; Jönsson L; Karampampa K; Knapp M; Kobelt G; Kurth T; Lieb R; Linde M; Ljungcrantz C; Maercker A; Melin B; Moscarelli M; Musayev A; Norwood F; Preisig M; Pugliatti M; Rehm J; Salvador-Carulla L; Schlehofer B; Simon R; Steinhausen HC; Stovner LJ; Vallat JM; Van den Bergh P; van Os J; Vos P; Xu W; Wittchen HU; Jönsson B; Olesen J;
    Eur Neuropsychopharmacol; 2011 Oct; 21(10):718-79. PubMed ID: 21924589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic Burden of Multiple Sclerosis in Low- and Middle-Income Countries: A Systematic Review.
    Dahham J; Rizk R; Kremer I; Evers SMAA; Hiligsmann M
    Pharmacoeconomics; 2021 Jul; 39(7):789-807. PubMed ID: 33956330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic burden of schizophrenia in Italy: a probabilistic cost of illness analysis.
    Marcellusi A; Fabiano G; Viti R; Francesa Morel PC; Nicolò G; Siracusano A; Mennini FS
    BMJ Open; 2018 Feb; 8(2):e018359. PubMed ID: 29439067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Societal costs of multiple sclerosis in Ireland.
    Carney P; O'Boyle D; Larkin A; McGuigan C; O'Rourke K
    J Med Econ; 2018 May; 21(5):425-437. PubMed ID: 29320900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic impact of multiple sclerosis in Italy: focus on rehabilitation costs.
    Ponzio M; Gerzeli S; Brichetto G; Bezzini D; Mancardi GL; Zaratin P; Battaglia MA
    Neurol Sci; 2015 Feb; 36(2):227-34. PubMed ID: 25109816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of Inflammatory Bowel Disease in Canada 2018: Indirect Costs of IBD Care.
    Kuenzig ME; Lee L; El-Matary W; Weizman AV; Benchimol EI; Kaplan GG; Nguyen GC; Bernstein CN; Bitton A; Lee K; Cooke-Lauder J; Murthy SK
    J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S34-S41. PubMed ID: 31294383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A literature review of cost-of-illness studies on the economic burden of multiple sclerosis.
    Paz-Zulueta M; Parás-Bravo P; Cantarero-Prieto D; Blázquez-Fernández C; Oterino-Durán A
    Mult Scler Relat Disord; 2020 Aug; 43():102162. PubMed ID: 32442885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The increasing economic burden of multiple sclerosis by disability severity in Australia in 2017: Results from updated and detailed data on types of costs.
    Ahmad H; Campbell JA; van der Mei I; Taylor BV; Zhao T; Palmer AJ
    Mult Scler Relat Disord; 2020 Sep; 44():102247. PubMed ID: 32554286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Societal costs of primary progressive multiple sclerosis in Australia and the economic impact of a hypothetical disease-modifying treatment that could delay disease progression.
    Brown LJ; Li J; Brunner M; Snoke M; La HA
    J Med Econ; 2021; 24(1):140-149. PubMed ID: 33461357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.